Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO - Seite 3

(4.2, NE) 3.6
(2.7, 4.4) NE
(5.4, NE) 3.9
(2.1, 4.7) 4.1
(1.6, 5.6) 3.6
(1.5, 5.0) HR (95% CI) 0.57
(0.37,0.90)* 0.33
(0.15, 0.72) 0.85
(0.49, 1.48)

*stratified
unstratified

At a six-month follow-up, the improvement in ORR (37.3% vs 20.6%) and PFS (median PFS=5.6 month versus 3.9 months) in the tiragolumab plus Tecentriq arm persisted in the ITT population. Results in the PD-L1-high population were also consistent with the first analysis and the median PFS was still not reached. 

Safety results

	tiragolumab + Tecentriq n=67	placebo + Tecentriq n= 68
All Grade 3-5 AEs	41.8%	44.1%
Treatment- related AEs (TRAEs)	80.6%	72%
Grade  ≥3 TRAEs	14.9%	19.1%
AEs leading to treatment withdrawal	7.5%	10.3%

About tiragolumab and TIGIT ⁵
Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells ^{2 3.} By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the body’s immune response ⁴. Blockade of TIGIT and PD-L1 may synergistically enable the re-activation of T-cells and enhance NK cell anti-tumour activity ^{2 6 7}.

About Tecentriq
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the activation of T-cells. Tecentriq is a cancer immunotherapy that has the potential to be used as a foundational combination partner with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. The development of Tecentriq and its clinical programme is based on our greater understanding of how the immune system interacts with tumours and how harnessing a person’s immune system combats cancer more effectively.